Akebia Therapeutics (AKBA) Share-based Compensation (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Share-based Compensation of $3.7 million for Q1 2026, up 67.72% year-over-year from $2.2 million in Q1 2025, and up 14.66% quarter-over-quarter from $3.2 million in Q4 2025.
Akebia Therapeutics (AKBA) Share-based Compensation (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Share-based Compensation for 14 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 67.72% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $12.8 million (up 67.9% YoY), while the FY2025 annual figure was $11.3 million, up 45.12% from the prior year.
- Share-based Compensation improved to $3.7 million in Q1 2026 per AKBA's latest filing, from $3.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.9 million in Q2 2022 and bottomed at $1.5 million in Q4 2023.
- Historically, Share-based Compensation has averaged $2.9 million across 5 years, with a median of $2.7 million in 2025.
- Annual changes were most pronounced in 2023 — Share-based Compensation slumped 50.21% — and 2025, when it soared 95.69%.
- Akebia Therapeutics' Share-based Compensation stood at $3.0 million in 2022, then plunged by 50.21% to $1.5 million in 2023, then rose by 12.09% to $1.7 million in 2024, then surged by 88.51% to $3.2 million in 2025, then gained by 14.66% to $3.7 million in 2026.
- Business Quant data shows AKBA's Share-based Compensation at $3.7 million in Q1 2026, $3.2 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 3.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.23 Mn |
| Jun 30, 2026 | 3.23 Mn |
| Mar 31, 2026 | 3.67 Mn |
| Mar 31, 2026 | 3.67 Mn |
| Dec 31, 2025 | 3.20 Mn |
| Dec 31, 2025 | 3.20 Mn |
| Sep 30, 2025 | 3.22 Mn |
| Sep 30, 2025 | 3.22 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.36 Mn |
| Mar 31, 2024 | 2.36 Mn |